Cargando…

Soluble CD163 and CD163 Expression on Monocytes Associated with Chronic Hepatitis B Inflammation and HBsAg Loss

BACKGROUND AND AIMS: Monocyte/macrophage-associated CD163 is an indicator of the severity of liver inflammation and cirrhosis, but the difference of soluble CD163 (sCD163) levels in chronic hepatitis B (CHB) patients and hepatitis B surface antigen (HBsAg)-loss patients is unclear. Herein, we aimed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Peilin, Yao, Bilian, Huang, Dao, Chen, Yongyan, Gong, Qiming, Zhang, Xinxin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	XIA & HE Publishing Inc. 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634769/ https://www.ncbi.nlm.nih.gov/pubmed/36381085 http://dx.doi.org/10.14218/JCTH.2021.00496

Ejemplares similares

Soluble ectodomain CD163 and extracellular vesicle-associated CD163 are two differently regulated forms of ‘soluble CD163’ in plasma
por: Etzerodt, Anders, et al.
Publicado: (2017)

Performance Evaluation of an Improved HBsAg Assay (HBsAg NEXT) for the Detection of HBsAg Levels
por: Gupta, Ekta, et al.
Publicado: (2023)

Soluble CD 163: A novel biomarker
por: Ahuja, Rajeev B.
Publicado: (2011)

Clinical Significance of Soluble Hemoglobin Scavenger Receptor CD163 (sCD163) in Sepsis, a Prospective Study
por: Feng, Lin, et al.
Publicado: (2012)

Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease
por: Nissen, Sara Konstantin, et al.
Publicado: (2020)

Local production of soluble CD163 in the spondyloarthropathic joint
por: Baeten, D, et al.
Publicado: (2003)

Soluble CD163 Identifies Those at Risk for Increased Hepatic Inflammation & Fibrosis
por: Sherman, Kenneth E, et al.
Publicado: (2021)

In vitro Phenotype Induction of Circulating Monocytes: CD16 and CD163 Analysis
por: Karsulovic, Claudio, et al.
Publicado: (2021)

Soluble CD163 as a Potential Biomarker in Systemic Sclerosis
por: Frantz, Camelia, et al.
Publicado: (2018)

Soluble CD163 in intracerebral hemorrhage: biomarker for perihematomal edema
por: Roy‐O'Reilly, Meaghan, et al.
Publicado: (2017)

CD16(+)CD163(+) monocytes traffic to sites of inflammation during necrotizing enterocolitis in premature infants
por: Olaloye, Oluwabunmi O., et al.
Publicado: (2021)

Relationship Between sCD163 and mCD163 and Their Implication in the Detection and Typing of Leprosy
por: Farag, Azza Gaber Antar, et al.
Publicado: (2020)

Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination
por: Galati, Giovanni, et al.
Publicado: (2014)

Monocyte Expression and Soluble Levels of the Haemoglobin Receptor (CD163/sCD163) and the Mannose Receptor (MR/sMR) in Septic and Critically Ill Non-Septic ICU Patients
por: Kjærgaard, Anders G., et al.
Publicado: (2014)

Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after nucleos(t)ide analog cessation
por: Xie, Yandi, et al.
Publicado: (2023)

CD14+CD16+ and CD14+CD163+ monocyte subpopulations in kidney allograft transplantation
por: Sekerkova, Alena, et al.
Publicado: (2014)

Soluble CD163 is produced by monocyte-derived and alveolar macrophages, and is not associated with the severity of idiopathic pulmonary fibrosis
por: Chauvin, Pierre, et al.
Publicado: (2022)

Soluble CD163-Associated Dietary Patterns and the Risk of Metabolic Syndrome
por: Hu, Tzu-Yu, et al.
Publicado: (2019)

Utility of Soluble CD163 in the Clinical Management of Patients With Kawasaki Disease
por: Azuma, Yoshihiro, et al.
Publicado: (2020)

Soluble CD163 Is a Predictor of Mortality in Patients With Decompensated Cirrhosis
por: Zhang, Yue, et al.
Publicado: (2021)

Comparison of the Clinical Features of Hepatitis A between HBsAg-Positive and HBsAg-Negative Patients
por: Kim, Kwang Min, et al.
Publicado: (2011)

Dilemma of HBsAg seroconversion in chronic hepatitis B infection: Dilemma of HBsAg in chronic HBV
por: Alavian, Seyed Moayed, et al.
Publicado: (2011)

Soluble CD163, a Product of Monocyte/Macrophage Activation, Is Inversely Associated with Haemoglobin Levels in Placental Malaria
por: Chua, Caroline Lin Lin, et al.
Publicado: (2013)

Contribution of NK cells to HBsAg seroconversion in inactive HBsAg carriers following pegylated IFN therapy
por: Cao, Zhenhuan, et al.
Publicado: (2020)

Comparative analysis of the safety and efficacy of HBsAg-1018 versus HBsAg-Eng: a meta-analysis
por: ZHANG, LIN L., et al.
Publicado: (2020)

B cells were related to HBsAg seroconversion in inactive HBsAg carriers following peginterferon therapy
por: Cao, Zhenhuan, et al.
Publicado: (2020)

CD163 as a Potential Biomarker of Monocyte Activation in Ischemic Stroke Patients
por: Greco, Rosaria, et al.
Publicado: (2021)

Recognition mechanisms of hemoglobin particles by monocytes – CD163 may just be one
por: Nimz, Jonathan-Gabriel, et al.
Publicado: (2023)

In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy
por: Kruse, Robert L., et al.
Publicado: (2017)

What are the causes and outcomes of the coexistence of HBsAg and anti-HBs?
por: Afyon, Murat
Publicado: (2016)

Urinary Soluble CD163 Levels Predict IgA Nephropathy Remission Status
por: Gong, Shaomin, et al.
Publicado: (2021)

Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis
por: Gantzel, Rasmus Hvidbjerg, et al.
Publicado: (2021)

Circulating immune complexes and mutations of HBsAg are associated with the undetectable HBsAg in anti-HBs and HBeAg positive occult hepatitis B virus infection
por: Yan, Ying, et al.
Publicado: (2022)

Long-term outcomes of HBsAg/anti-HBs double-positive versus HBsAg single-positive patients with chronic hepatitis B
por: Kwak, Min-Sun, et al.
Publicado: (2019)

Comparison of Serum HBsAg Quantitation by Four Immunoassays, and Relationships of HBsAg Level with HBV Replication and HBV Genotypes
por: Tuaillon, Edouard, et al.
Publicado: (2012)

Assessment of noninvasive liver stiffness in inactive HBsAg carriers by transient elastography: Fibroscan in inactive HBsAg carriers
por: Sporea, Ioan, et al.
Publicado: (2011)

Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro
por: Salpini, Romina, et al.
Publicado: (2017)

Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon
por: Li, Hong, et al.
Publicado: (2022)

The potential effect of HBV vaccination on off-treatment HBsAg reversion after interferon-induced HBsAg clearance
por: Jiang, Shaowen, et al.
Publicado: (2023)

Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs
por: Huang, Jing, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_et74978vje4o9n5i94i1b5823o